Health Care
Polynovo Ltd (PNV)
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Market Cap
A$691M
Shares on Issue
0.67B
Price Chart
AI Analysis
Polynovo continues to grow sales of NovoSorb across global markets, supported by clinician adoption and recurring hospital demand. Expansion into new indications provides incremental growth potential.
Investment in manufacturing capacity and sales teams is aimed at sustaining long-term market penetration while maintaining high gross margins.
Bull Case
- • Strong product adoption supports revenue growth.
- • International expansion broadens addressable market.
- • High-margin consumables drive profitability.
Bear Case
- • Hospital budget pressures could slow adoption.
- • Competition in wound care may limit pricing power.
- • Execution risk in scaling manufacturing.
Market Sentiment
Based on 9 social posts
Recent mentions
Record sales reported by PolyNovo
Neutral post with no opinion or sentiment expressed
Neutral post with no opinion or information about the stock
Recent Announcements
Change of Director's Interest Notice - Robert Douglas
Director Appointment - Charmaine Gittleson
Initial Director's Interest Notice - Charmaine Gittleson
FAQs
What does Polynovo sell?
Polynovo sells NovoSorb biodegradable polymer products for wound care.
Is PNV profitable?
Polynovo is transitioning toward profitability as revenue scales.
What drives PNV growth?
Clinician adoption, hospital penetration, and new indications are key.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$138.93
-43.8% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
1ADAdalta Limited
A$0.00
33.3% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.
Health Care
1AIAlgorae Pharmaceuticals Limited
A$0.02
166.7% 1Y
Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.